News

Actelion: up to 135 jobs lost
Enlarge image

BusinessSwitzerland

Actelion: up to 135 jobs lost

13.07.2012 - Swiss biotech company Actelion announces to reduce headcount by 135 in order to lower costs and refocus research.

The swiss pharma company is relying heavily on 1st main product, the blood-pressure drug Tracleer, which currently accounts for around 90 percent of group sales and goes off patent in 2015. As the sales of the endothelin receptor antagonist decline, Actelion decided to start a cost saving initiative. "In order to take full advantage of the growth opportunities ahead of us, we must take decisive action now," said Chief Executive Jean-Paul Clozel.

The cost savings will reduce research spending. Actelion is set to concentrate 1st R&D activities towards orphan and speciality indications. Projects „which are not in alignment with this strategy will either be stopped, or prepared for partnership or out-licensing“, the Swiss company stated on 12 June. The cuts will be the first at Actelion since it was founded in 1997 and will mostly hit the headquarters in Allschwil. Around 70 jobs, mostly in R&D and general administration, are likely go at the Allschwil site in Switzerland, where 1,100 employees are currently based. Another 45 currently vacant positions won't be filled, reports Fox Business.

“It’s good to see they’re doing the right thing,” Michael Leuchten, an analyst at Barclays Capital in London, said to Bloomberg, adding that it would be „a bit more than they had been talking about” at a briefing in May, when the company said it would seek cost reductions in research, and not administration. Analyst Birgit Kulhoff, who manages a healthcare portfolio for private bank Rahn & Bodmer in Zurich is more sceptical. She said, that Actelion's cost-cutting scheme would merely aim at keeping the company afloat, after it had built up a structure that was too big and hard to sustain. Vontobel analyst Andrew Weiss expects the job cuts to generate savings of about CHF40m, while the related charges could be in the area of CHF20 million. Actelion will provide a will provide a business update at the half year reporting, scheduled for 19 July 2012.

http://www.european-biotechnology-news.com/news/news/2012-03/actelion-up-to-135-jobs-lost.html

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Drug AssessmentPortugalFrance

18.01.2016 A Phase I clinical trial for a drug developed by Portuguese pharma company Bial has ended in disaster. One man died, five others may have irreversible neurological damage.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SAREUM HOLDINGS (UK)0.25 GBP8.70%
  • MAGFORCE (D)5.25 EUR5.00%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • EVOCUTIS (UK)0.07 GBP-12.50%

TOP

  • VERONA PHARMA (UK)3.50 GBP32.1%
  • WILEX (D)2.09 EUR22.9%
  • IXICO (UK)34.00 GBP15.3%

FLOP

  • BIONOR PHARMA (N)0.88 NOK-43.6%
  • PROTHENA PLC (IE)34.27 USD-36.4%
  • PLETHORA (UK)2.75 GBP-33.3%

TOP

  • KARO BIO (S)26.80 SEK3728.6%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • 4SC (D)3.33 EUR282.8%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.80 SEK-85.6%
  • BIOTEST (D)14.11 EUR-84.6%
  • EVOCUTIS (UK)0.07 GBP-75.0%

No liability assumed, Date: 08.02.2016